These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 37937357)
1. Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners. Anagnostis P; Antza C; Florentin M; Kotsis V Kardiol Pol; 2023; 81(11):1081-1088. PubMed ID: 37937357 [TBL] [Abstract][Full Text] [Related]
11. Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA). Tarugi P; Bertolini S; Calandra S; Arca M; Angelico F; Casula M; Cefalù AB; D'Erasmo L; Fortunato G; Perrone-Filardi P; Rubba P; Suppressa P; Averna M; Catapano AL Nutr Metab Cardiovasc Dis; 2024 Aug; 34(8):1819-1836. PubMed ID: 38871496 [TBL] [Abstract][Full Text] [Related]
12. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Polychronopoulos G; Tziomalos K Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760 [TBL] [Abstract][Full Text] [Related]
14. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071 [TBL] [Abstract][Full Text] [Related]
16. Familial hypercholesterolemia treatments: Guidelines and new therapies. Raal FJ; Hovingh GK; Catapano AL Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089 [TBL] [Abstract][Full Text] [Related]
17. Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents. Cohen H; Stefanutti C; Curr Atheroscler Rep; 2021 May; 23(6):30. PubMed ID: 33963467 [TBL] [Abstract][Full Text] [Related]
18. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies. Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL; J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591 [TBL] [Abstract][Full Text] [Related]
20. Inclisiran: A Review in Hypercholesterolemia. Frampton JE Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]